PUBLIC COMPANY
save$INSMINSMED Inc
$INSM115.63-1.73%Bridgewater, NJ, USupdated 1d ago
community read0 votes
🐶 often sniffed alongside
top 4pipeline
6
marketed
2
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Phase 11Phase 32Marketed1Unknown
Marketed
amikacin sulfate PR
Lung Infections
Bacterial 70S ribosome
Marketedbrensocatib
Bronchiectasis
Phase 3treprostinil palmitil
Pulmonary Arterial Hypertension
Phase 1INS-1201
Duchenne Muscular Dystrophy
Phase 1INS-1202
Amyotrophic Lateral Sclerosis
drugARIKAYCE KIT
respiratory tract infectious disorder
Bacterial 70S ribosome
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
- phase1A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants
- phase3Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase1A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- phase3An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase3An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
- phase2A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- phase3A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 16, 26SELLLewis William· Chair and CEO−$773K↗
- Apr 16, 26SELLLewis William· Chair and CEO−$326K↗
- Apr 16, 26SELLLewis William· Chair and CEO−$321K↗
- Apr 16, 26SELLLewis William· Chair and CEO−$120K↗
- Apr 6, 26SELLLewis William· Chair and CEO−$1.38M↗
- Apr 6, 26SELLLewis William· Chair and CEO−$235K↗
- Apr 6, 26SELLLewis William· Chair and CEO−$127K↗
routine RSU / option mechanics (6)
- Apr 16, 26option exerciseLewis William · Chair and CEO6,259 sh
- Apr 16, 26option exerciseLewis William · Chair and CEO4,440 sh
- Apr 16, 26option exerciseLewis William · Chair and CEO4,440 sh
- Apr 16, 26option exerciseLewis William · Chair and CEO6,259 sh
- Apr 6, 26option exerciseLewis William · Chair and CEO6,259 sh
- Apr 6, 26option exerciseLewis William · Chair and CEO4,440 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that